Multicenter Selective Lymphadenectomy Trial (MSLT)
A Clinical Study of Wide Excision Alone Versus Wide Excision With Intraoperative Lymphatic Mapping and Selective Lymph Node Dissection in the Treatment of Patients With Cutaneous Invasive Melanoma.
Sponsor: National Institutes of Health (NIH)
This PHASE3 trial investigates Melanoma and is currently completed. National Institutes of Health (NIH) leads this study, which shows 6 recorded versions since 1993 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 1993
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institutes of Health (NIH)
- Saint John's Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.